|
|
Vaccine Comparison
|
Avirulent Salmonella vaccine strain carrying C. jejuni cjaA gene |
| Vaccine Information |
- Vaccine Name: Avirulent Salmonella vaccine strain carrying C. jejuni cjaA gene
- Vaccine Ontology ID: VO_0004121
- Type: Recombinant vector vaccine
- Antigen: Three C jejuni genes [cjaA ( cj0982c ) , cjaC ( cj0734c ) and cjaD ( cj0113 )] encoding highly immunogenic proteins which are conserved among different Campylobacter serotypes have been introduced into avirulent Salmonella enterica sv. Typhimurium (chi 4550 and chi 3987) strains of two different serotypes (UK-1 and SR) (Wyszynska et al., 2004). C. jejuni 72Dz/92 cjaA gene encodes a highly immunogenic protein which is conserved among different Campylobacter serotypes (Wyszynska et al., 2004). The surface antigen CjaA of Campylobacter jejuni is supported by the presence of an upstream gene with significant homology to ATP binding proteins (Martin et al., 1999).
- cjaA
gene engineering:
- Type: Recombinant vector construction
- Description: pUWA10A plasmid carrying CjaA was ligated into the pYA3341 plasmid and then transformed into E. coli χ6097 competent cells. It was later introduced by electroporation into two S. enterica sv. Typhimurium (χ3987 and χ4550) strains (Wyszynska et al., 2004).
- Detailed Gene Information: Click Here.
- Adjuvant:
- Preparation: Three gene libraries of Campylobacter jejuni 72Dz/92 DNA were prepared using lambda gt11, pSupercos and pWSK129 cloning vectors. Screening of the libraries revealed several immunoreactive clones (Pawelec et al., 1997).
- Virulence: The vaccine vector is avirulent Salmonella enterica sv. Typhimurium (chi 4550 and chi 3987) strains of two different serotypes (UK-1 and SR) (Wyszynska et al., 2004).
- Description: The constitutive expression of all analysed genes as measured by Western immunoblot technique was independent of the particular host strain. Specific rabbit anti-rCjaA antibody reacted not only with CjaA but also with other solute-binding proteins, components of the ABC transport system (CjaC protein), chosen as the protective antigen for animal experiments. Chickens orally immunized with Salmonella expressing Campylobacter cjaA gene developed serum IgG and mucosal IgA antibody responses against Campylobacter membrane proteins and Salmonella OMPs. Protection experiments show that chicken immunization with avirulent Salmonella carrying Campylobacter cjaA gene greatly reduces ability of heterologous wild type C. jejuni strain to colonize the bird cecum (Wyszynska et al., 2004).
|
| References |
Martin et al., 1999: Martin PR, Mulks MH. Cloning and characterization of a gene encoding an antigenic membrane protein from Actinobacillus pleuropneumoniae with homology to ABC transporters. FEMS immunology and medical microbiology. 1999 Aug 15; 25(3); 245-54. [PubMed: 10459579].
Pawelec et al., 1997: Pawelec D, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium. FEMS immunology and medical microbiology. 1997 Oct; 19(2); 137-50. [PubMed: 9395059].
Wyszynska et al., 2004: Wyszynska A, Raczko A, Lis M, Jagusztyn-Krynicka EK. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine. 2004 Mar 29; 22(11-12); 1379-89. [PubMed: 15063560 ].
|
|
B. burgdorferi OspB Protein Vaccine |
| Vaccine Information |
- Vaccine Name: B. burgdorferi OspB Protein Vaccine
- Vaccine Ontology ID: VO_0004029
- Type: Recombinant vector vaccine
- Status: Research
- Antigen: Recombinant OspB protein
- OspB
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Adjuvant:
- Adjuvant:
- Immunization Route: Intraperitoneal injection (i.p.)
|
| References |
|
|
|
B. melitensis bp26 and TF Nasal Vaccine |
| Vaccine Information |
- Vaccine Name: B. melitensis bp26 and TF Nasal Vaccine
- Vaccine Ontology ID: VO_0000411
- Type: Recombinant vector vaccine
- Antigen: Purified Brucella bp26 and trigger factor (Tf) proteins, also called Tig (Yang et al., 2007).
- Tig
gene engineering:
- Type: Recombinant protein preparation
- Description: Recombinant bp26 and Tf were produced in Pichia pastoris and purified, and mixed with cholera toxin (CT) adjuvant(Yang et al., 2007).
- Detailed Gene Information: Click Here.
- Adjuvant:
- VO ID: VO_0000143
- Description: Cholera toxin (CT) was used as the adjuvant for this vaccine (Yang et al., 2007).
- Preparation: Recombinant bp26 and Tf were produced in Pichia pastoris and purified. Each vaccine consisted of either 50 or 100 micrograms per dose of either bp26, Tf, or both combined with the CT adjuvant (Yang et al., 2007).
|
| References |
Yang et al., 2007: Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine. 2007; 25(12); 2261-2268. [PubMed: 17239499].
|
|
Epivac vaccine |
| Vaccine Information |
- Vaccine Name: Epivac vaccine
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Host Species as Laboratory Animal Model: Mice
- cagA
gene engineering:
- Type: Recombinant protein preparation
- Description: Compared to non-immunized mice, immunization with Epivac alone or with a Th1 adjuvant significantly reduced H. pylori colonization, and better protection was observed when an adjuvant was used (Li et al., 2012).
- Detailed Gene Information: Click Here.
- Adjuvant:
- VO ID: VO_0001237
- Description: In six groups, mice (n = 10) were immunized three times at two-week intervals with PBS, Epivac or Epivac plus one of the following four Th1 adjuvants: CpG ODN 1826 (CpG, 20 μg/mouse, synthesized by Invitrogen), N-glycolyl-MDP VacciGrade (MDP, 30 μg/mouse, InvivoGen), MPLA VacciGrade (MPLA, 10 μg/mouse, InvivoGen) and Addavax (1:1, InvivoGen) (Li et al., 2012).
- Immunization Route: subcutaneous injection
|
| References |
Li et al., 2012: Li HB, Zhang JY, He YF, Chen L, Li B, Liu KY, Yang WC, Zhao Z, Zou QM, Wu C. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine. 2012; 31(1); 120-126. [PubMed: 23137845].
|
|
Recombinant O. anthropi 49237SOD |
| Vaccine Information |
- Vaccine Name: Recombinant O. anthropi 49237SOD
- Vaccine Ontology ID: VO_0000407
- Type: Recombinant vector vaccine
- Adjuvant:
- Preparation: Ochrobactrum anthropi strain 47237 was originally isolated from soil. Plasmids pBBSOD and pBBR1MCS were electroporated into electrocompetent O. anthropi strain 49237 using a protocol described previously for Brucella. Colonies of the O. anthropi strain 49237 containing pBBSOD or pBBR1MCS (designated O. anthropi strain 49237SOD or 49237pBB, respectively) were selected from TSA plates containing chloramphenicol at a concentration of 30 μg/ml (He et al., 2002)
- Virulence: O. anthropi strains are rarely pathogenic to humans (He et al., 2002)
- Description: Ochrobactrum anthropi is very closely related to Brucella, and has been used as a vaccine or vaccine vector for Brucellosis (He et al., 2002).
|
| References |
He et al., 2002: He Y, Vemulapalli R, Schurig GG. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infection and immunity. 2002 May; 70(5); 2535-43. [PubMed: 11953393].
|
|
Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein |
| Vaccine Information |
|
|
| References |
Crocquet-Valdes et al., 2001: Crocquet-Valdes PA, Díaz-Montero CM, Feng HM, Li H, Barrett AD, Walker DH. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine. 2001; 20(5-6); 979-988. [PubMed: 11738766].
|
|
